1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Pennsylvania >
  6. Medivir Acquires TetraLogic Pharmaceuticals - Oncology Programs

M&A Deal Summary

Medivir Acquires TetraLogic Pharmaceuticals - Oncology Programs

On December 29, 2016, Medivir acquired life science company TetraLogic Pharmaceuticals - Oncology Programs from TetraLogic Pharmaceuticals for 12M USD

Acquisition Highlights
  • This is Medivir’s 3rd transaction in the Life Science sector.
  • This is Medivir’s largest (disclosed) transaction.
  • This is Medivir’s 1st transaction in the United States.
  • This is Medivir’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2016-12-29
Target TetraLogic Pharmaceuticals - Oncology Programs
Sector Life Science
Buyer(s) Medivir
Sellers(s) TetraLogic Pharmaceuticals
Deal Type Divestiture
Deal Value 12M USD

Target

TetraLogic Pharmaceuticals - Oncology Programs

Malvern, Pennsylvania, United States
TetraLogic Pharmaceuticals Corp. - Oncology Programs includes clinical stage oncology programs MAC Mimetic and HDAC Inhibitor Assets.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Medivir

Huddinge, Sweden
Category Company
Founded 1987
Sector Life Science
Employees10
Revenue 3M SEK (2024)
DESCRIPTION

Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. Medivir is a competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir was founded in 1987 and is based in Huddinge, Sweden.

DEAL STATS #
Overall 4 of 4
Sector: Life Science M&A 3 of 3
Type: Divestiture M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2016 M&A 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-11-01 Biophausia AB

Stockholm, Sweden

Biophausia AB is a pharmaceutical company. Biophausia provides cost-effective pharmaceuticals and focuses on three fields: generic products, niche products and original drugs.

Sell kr908M

Seller(S) 1

SELLER

TetraLogic Pharmaceuticals

Malvern, Pennsylvania, United States
Category Company
Founded 2001
Sector Life Science
Employees29
DESCRIPTION

TetraLogic Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring and developing novel product candidates to treat cancer and infectious diseases. TetraLogic Pharmaceuticals was incorporated in 2001 and is based in Malvern, Pennsylvania.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2016 M&A 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-04-14 Shape Pharmaceuticals

Cambridge, Massachusetts, United States

Shape PharmacShape Pharmaceuticals, a privately-held biotechnology company developing suberohydroxamic acid phenyl ester (SHAPE).

Buy -
Mergr

Solution for

Product

Company

Legal